Alex Denner, Ph.D., has been investing in health-care companies for the past two decades. In 2013 he founded Sarissa Capital Management LP, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the health-care sector. Sarissa focuses on improving the strategies of health-care companies to enhance shareholder value.
Denner has led Sarissa’s involvement in some of biopharma’s most successful strategic transactions and activist campaigns, including the sale of Idenix to Merck, the sale of ARIAD to Takeda, the spin-off from Biogen and subsequent sale of Bioverativ to Sanofi and the recent announcement by Ironwood Pharmaceuticals to separate its commercialized products business from its R&D platform, among others.
Prior to founding Sarissa, Denner was the health-care portfolio manager of Icahn Capital. At Icahn Capital, Denner developed Carl Icahn’s activist strategy in health care and was responsible for some of Icahn’s most successful investments, including ImClone, Genzyme, Amylin, Biogen and Forest Laboratories. In the decade prior to joining Icahn Capital, Denner honed his skills as a fundamental, value-based health-care investor first at Morgan Stanley Investment Management and then at Viking Global Investors.
Denner currently serves as a director of Biogen and a director and chairman of The Medicines Company. He previously served as a director and chairman of ARIAD Pharmaceuticals and director of Amylin Pharmaceuticals, Bioverativ and ImClone Systems, where he was also chairman of the executive committee.
Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil. and Ph.D. degrees from Yale University.